OB/GYN providers practice in a social and political setting that can lead to poor mental health, which is driving a mental health crisis, according to a speaker at the ACOG Annual Clinical & Scientific Meeting.
“There’s no question we are living during turbulent times, and your specialty is certainly caught in the crosshairs,” Samantha Meltzer-Brody, MD, MPH, said. “One of the things that’s very clear is that health care has been under attack. … It can feel like there’s a tsunami that’s hitting us each day.”
OB/GYN providers practice in a social and political setting that can lead to poor mental health, which is driving a mental health crisis, according to a speaker at the ACOG Annual Clinical & Scientific Meeting. Image: Adobe Stock
This was the top story in women’s health last week.
Another story was a Q&A with Audrey Blondin, JD, MPH, an adjunct faculty member at the University of New Haven School of Health Sciences in Connecticut, about the legalities of mifepristone and predictions for future case outcomes on abortion access.
Read these and more top stories in women’s health below:
Women’s health providers face mental health ‘tsunami’
The pandemic, political discord, misinformation and what the U.S. Surgeon General has called an “epidemic of loneliness and isolation,” confront OB/GYN providers as intensely as the rest of the population, according to a speaker. Read more.
Q&A: Mifepristone withdrawal unlikely; future of medication abortion
Since the Dobbs decision in June 2022 that overturned the federal right to abortion, access to abortion and abortifacient drugs has been a source of debate for physicians and legislators. Read more.
Q&A: Health changes during menopause associated with increased cardiovascular risk
During the transition to menopause many women may experience adverse changes to multiple cardiovascular risk factors, according to a North American Menopause Society Practice Pearl published in Menopause. Read more.
Combined estrogen plus progestin for menopausal symptoms not linked to type 2 diabetes risk
Risk for type 2 diabetes with use of menopausal hormone therapy varied by type of hormone therapy, according to a retrospective cohort study of women in South Korea published in Menopause. Read more.
Court hears oral arguments in next stage of mifepristone abortion pill legal challenge
Parties to the federal case seeking to overturn FDA approval of the abortion drug mifepristone presented oral arguments to a panel of three judges in the 5th U.S. Circuit Court of Appeals. Read more.
